BCX

Bioceltix WSE:BCX Stock Report

Last Price

zł36.40

Market Cap

zł119.6m

7D

-2.4%

1Y

n/a

Updated

22 May, 2022

Data

Company Financials
BCX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

BCX Stock Overview

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use.

Bioceltix Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Bioceltix
Historical stock prices
Current Share Pricezł36.40
52 Week Highzł69.00
52 Week Lowzł30.10
Beta0
1 Month Change-1.62%
3 Month Change-11.22%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO4.00%

Recent News & Updates

Shareholder Returns

BCXPL BiotechsPL Market
7D-2.4%-1.7%0.9%
1Yn/a-40.0%-15.6%

Return vs Industry: Insufficient data to determine how BCX performed against the Polish Biotechs industry.

Return vs Market: Insufficient data to determine how BCX performed against the Polish Market.

Price Volatility

Is BCX's price volatile compared to industry and market?
BCX volatility
BCX Average Weekly Movement7.3%
Biotechs Industry Average Movement8.6%
Market Average Movement7.7%
10% most volatile stocks in PL Market14.7%
10% least volatile stocks in PL Market5.1%

Stable Share Price: BCX is not significantly more volatile than the rest of Polish stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: BCX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aGrzegorz Ostropolskihttps://bioceltix.com

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company is based in Wroclaw, Poland.

Bioceltix Fundamentals Summary

How do Bioceltix's earnings and revenue compare to its market cap?
BCX fundamental statistics
Market Capzł119.64m
Earnings (TTM)zł0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BCX income statement (TTM)
Revenuezł0
Cost of Revenuezł0
Gross Profitzł0
Other Expenseszł0
Earningszł0

Last Reported Earnings

n/a

Next Earnings Date

Aug 11, 2022

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did BCX perform over the long term?

See historical performance and comparison

Valuation

Is Bioceltix undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry

In this section, we usually try to help investors determine whether Bioceltix is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bioceltix has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Bioceltix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


42.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioceltix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Bioceltix performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


40.0%

Historical Pharmaceuticals & Biotech annual earnings growth

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Bioceltix has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Financial Health

How is Bioceltix's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

In this section we usually analyse Bioceltix's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Bioceltix has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Dividend

What is Bioceltix current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BCX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BCX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BCX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BCX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BCX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Grzegorz Ostropolski

no data

Tenure

Mr. Grzegorz Ostropolski serves as Chief Executive Officer at Bioceltix S.A. He gained experience in international corporations in creating new production organizations and implemented new products on glob...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: BCX only recently listed within the past 12 months.


Top Shareholders

Company Information

Bioceltix S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Bioceltix S.A.
  • Ticker: BCX
  • Exchange: WSE
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł119.639m
  • Shares outstanding: 3.29m
  • Website: https://bioceltix.com

Location

  • Bioceltix S.A.
  • Building III
  • Bierutowska 57-59 Street
  • Wroclaw
  • 52-326
  • Poland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
EarningsN/A
Annual EarningsN/A


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.